Deal Size Increased to $85M in Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy SABS?
The deal size was increased to $85M in common stock from $75M in common stock and the range was $3.75-$4.07. Jefferies, UBS, Citi and Barclays acted as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SABS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SABS
Wall Street analysts forecast SABS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.830
Low
7.00
Averages
10.33
High
15.00
Current: 3.830
Low
7.00
Averages
10.33
High
15.00
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SAB Biotherapeutics Completes $85M Stock Offering
- Offering Size: SAB Biotherapeutics priced approximately 19.32 million common shares at $3.85 each, raising a total of $85 million, indicating the company's proactive approach to securing funding.
- Clear Use of Proceeds: The net proceeds from this offering will primarily be allocated to advancing SAB-142 clinical trials, manufacturing, regulatory efforts, and operations, while also bolstering working capital to ensure sufficient funding during critical R&D phases.
- Underwriter's Option: The underwriters have a 30-day option to purchase an additional ~3.31 million shares, providing the company with flexibility for further financing, which could help address future capital needs.
- Market Reaction: Following the announcement of the stock offering, SAB Biotherapeutics' stock price dropped about 5% in after-hours trading on Tuesday, reflecting a cautious market sentiment that may impact investor confidence.
See More
SAB Biotherapeutics Launches Public Offering to Fund Diabetes Candidate
- Public Offering Initiated: SAB Biotherapeutics (SABS) has launched an underwritten public offering of common stock and pre-funded warrants, which is expected to provide significant funding support for the company.
- Additional Securities Option: The offering includes an option for underwriters to purchase up to 15% additional securities within 30 days, a flexibility that may attract more investor participation.
- Clear Use of Proceeds: Proceeds from the offering will primarily support the development of its lead candidate SAB-142 for Type 1 Diabetes, while also covering clinical trials, manufacturing, regulatory activities, and general corporate expenses, ensuring smooth project advancement.
- Negative Market Reaction: Following the public offering announcement, SABS shares fell 6.9% in after-hours trading, reflecting market caution regarding the financing, which may impact the company's future fundraising capabilities.
See More
SAB Biotherapeutics Reports Positive Phase 1 Data for SAB-142 in T1D
- C-Peptide Preservation: In a cohort of six T1D patients, four treated with SAB-142 showed no decrease in C-peptide levels at Day 120, indicating potential efficacy that could transform T1D treatment paradigms.
- Clinical Trial Design: The Phase 1 trial utilized a randomized, double-blind, placebo-controlled design aimed at assessing the safety and pharmacodynamics of SAB-142, establishing a foundation for the subsequent Phase 2b trial, with topline data expected in the second half of 2027.
- Biomarker Support: Preliminary data indicate that biomarkers of T cell exhaustion align with preserved C-peptide levels, enhancing confidence in SAB-142's mechanism of action and potentially offering new treatment options for patients.
- Market Potential: As a potential disease-modifying therapy, SAB-142 could change the treatment landscape for T1D, addressing the urgent need for novel therapies among patients and further driving the company's growth in the biopharmaceutical sector.
See More
SAB Biotherapeutics Reports 2025 Financial Highlights
- Net Income Improvement: SAB Biotherapeutics reported a net income of $13.3 million for 2025, a significant turnaround from a net loss of $34.1 million in 2024, indicating a strong recovery in financial performance that boosts investor confidence.
- Strong Cash Position: As of December 31, 2025, the company held $143.5 million in cash, cash equivalents, and available-for-sale securities, providing a solid operational runway through 2028, which enhances its long-term growth potential.
- Increased R&D Spending: Research and development expenses rose to $34.4 million in 2025 from $30.3 million in 2024, reflecting the company's ongoing commitment to innovation and product development, which is crucial for maintaining competitive advantage in the market.
- Significant Other Income Growth: Other income surged to $62.2 million in 2025, up from $8.8 million in 2024, primarily driven by changes in the fair value of warrant liabilities, showcasing effective financial management and strategic asset utilization.
See More
SAB Biotherapeutics Advances SAB-142 into Phase 2b Clinical Study
- Clinical Study Progress: SAB Biotherapeutics has dosed multiple patients in the registrational Phase 2b SAFEGUARD study of SAB-142, with enrollment expected to complete by the end of 2026 and topline data anticipated in the second half of 2027, indicating significant advancements in treating type 1 diabetes.
- Successful Financing: The company raised $175 million in an oversubscribed private placement, fully funding the SAFEGUARD study, which not only strengthens its financial position but also secures the necessary resources for ongoing clinical development.
- Positive Clinical Data: Phase 1 trials of SAB-142 in healthy volunteers and T1D cohorts demonstrated a favorable safety profile and low immunogenicity, supporting its potential for chronic outpatient administration, thereby opening new avenues for type 1 diabetes treatment.
- Executive Appointments: David Zaccardelli and Rita Jain have been appointed as Chair and Independent Director of the Board, respectively, both bringing over 20 years of experience in biopharmaceuticals, which is expected to enhance the company's strategic direction and clinical research efforts.
See More
SAB Biotherapeutics Promotes SAB-142 for Type 1 Diabetes at Oppenheimer Conference
- Trial Design: SAB-142 is being evaluated in the global Phase IIb SAFEGUARD trial targeting newly diagnosed Stage 3 T1D patients with dosing every six months across three arms (2.5 mg/kg, 1.5 mg/kg, and placebo), with a primary endpoint of C-peptide at one year, aiming for last patient in by end-2026 and top-line data in H2 2027.
- Market Potential: SAB identifies an initial addressable market of approximately 64,000 new Stage 3 diagnoses annually in the U.S., and with Tzield priced at $200,000, SAB-142 presents a significant market opportunity, especially as redosing could expand commercial prospects to meet urgent patient needs.
- Financial Position: Ending 2025 with $140 million in cash, SAB is well-positioned to fund the SAFEGUARD trial through top-line readout and into 2028, ensuring adequate financial resources during critical development phases.
- Technical Advantages: As a fully human anti-thymocyte globulin, SAB-142 avoids the serum sickness and anti-drug antibody issues associated with rabbit ATG, offering better tolerability and redosing capabilities, aimed at inducing T-cell exhaustion to protect pancreatic beta cells and enhance insulin production in patients.
See More
SAB Biotherapeutics Completes $85M Stock Offering
- Offering Size: SAB Biotherapeutics priced approximately 19.32 million common shares at $3.85 each, raising a total of $85 million, indicating the company's proactive approach to securing funding.
- Clear Use of Proceeds: The net proceeds from this offering will primarily be allocated to advancing SAB-142 clinical trials, manufacturing, regulatory efforts, and operations, while also bolstering working capital to ensure sufficient funding during critical R&D phases.
- Underwriter's Option: The underwriters have a 30-day option to purchase an additional ~3.31 million shares, providing the company with flexibility for further financing, which could help address future capital needs.
- Market Reaction: Following the announcement of the stock offering, SAB Biotherapeutics' stock price dropped about 5% in after-hours trading on Tuesday, reflecting a cautious market sentiment that may impact investor confidence.
See More
SAB Biotherapeutics Launches Public Offering to Fund Diabetes Candidate
- Public Offering Initiated: SAB Biotherapeutics (SABS) has launched an underwritten public offering of common stock and pre-funded warrants, which is expected to provide significant funding support for the company.
- Additional Securities Option: The offering includes an option for underwriters to purchase up to 15% additional securities within 30 days, a flexibility that may attract more investor participation.
- Clear Use of Proceeds: Proceeds from the offering will primarily support the development of its lead candidate SAB-142 for Type 1 Diabetes, while also covering clinical trials, manufacturing, regulatory activities, and general corporate expenses, ensuring smooth project advancement.
- Negative Market Reaction: Following the public offering announcement, SABS shares fell 6.9% in after-hours trading, reflecting market caution regarding the financing, which may impact the company's future fundraising capabilities.
See More
SAB Biotherapeutics Reports Positive Phase 1 Data for SAB-142 in T1D
- C-Peptide Preservation: In a cohort of six T1D patients, four treated with SAB-142 showed no decrease in C-peptide levels at Day 120, indicating potential efficacy that could transform T1D treatment paradigms.
- Clinical Trial Design: The Phase 1 trial utilized a randomized, double-blind, placebo-controlled design aimed at assessing the safety and pharmacodynamics of SAB-142, establishing a foundation for the subsequent Phase 2b trial, with topline data expected in the second half of 2027.
- Biomarker Support: Preliminary data indicate that biomarkers of T cell exhaustion align with preserved C-peptide levels, enhancing confidence in SAB-142's mechanism of action and potentially offering new treatment options for patients.
- Market Potential: As a potential disease-modifying therapy, SAB-142 could change the treatment landscape for T1D, addressing the urgent need for novel therapies among patients and further driving the company's growth in the biopharmaceutical sector.
See More
SAB Biotherapeutics Reports 2025 Financial Highlights
- Net Income Improvement: SAB Biotherapeutics reported a net income of $13.3 million for 2025, a significant turnaround from a net loss of $34.1 million in 2024, indicating a strong recovery in financial performance that boosts investor confidence.
- Strong Cash Position: As of December 31, 2025, the company held $143.5 million in cash, cash equivalents, and available-for-sale securities, providing a solid operational runway through 2028, which enhances its long-term growth potential.
- Increased R&D Spending: Research and development expenses rose to $34.4 million in 2025 from $30.3 million in 2024, reflecting the company's ongoing commitment to innovation and product development, which is crucial for maintaining competitive advantage in the market.
- Significant Other Income Growth: Other income surged to $62.2 million in 2025, up from $8.8 million in 2024, primarily driven by changes in the fair value of warrant liabilities, showcasing effective financial management and strategic asset utilization.
See More
SAB Biotherapeutics Advances SAB-142 into Phase 2b Clinical Study
- Clinical Study Progress: SAB Biotherapeutics has dosed multiple patients in the registrational Phase 2b SAFEGUARD study of SAB-142, with enrollment expected to complete by the end of 2026 and topline data anticipated in the second half of 2027, indicating significant advancements in treating type 1 diabetes.
- Successful Financing: The company raised $175 million in an oversubscribed private placement, fully funding the SAFEGUARD study, which not only strengthens its financial position but also secures the necessary resources for ongoing clinical development.
- Positive Clinical Data: Phase 1 trials of SAB-142 in healthy volunteers and T1D cohorts demonstrated a favorable safety profile and low immunogenicity, supporting its potential for chronic outpatient administration, thereby opening new avenues for type 1 diabetes treatment.
- Executive Appointments: David Zaccardelli and Rita Jain have been appointed as Chair and Independent Director of the Board, respectively, both bringing over 20 years of experience in biopharmaceuticals, which is expected to enhance the company's strategic direction and clinical research efforts.
See More
SAB Biotherapeutics Promotes SAB-142 for Type 1 Diabetes at Oppenheimer Conference
- Trial Design: SAB-142 is being evaluated in the global Phase IIb SAFEGUARD trial targeting newly diagnosed Stage 3 T1D patients with dosing every six months across three arms (2.5 mg/kg, 1.5 mg/kg, and placebo), with a primary endpoint of C-peptide at one year, aiming for last patient in by end-2026 and top-line data in H2 2027.
- Market Potential: SAB identifies an initial addressable market of approximately 64,000 new Stage 3 diagnoses annually in the U.S., and with Tzield priced at $200,000, SAB-142 presents a significant market opportunity, especially as redosing could expand commercial prospects to meet urgent patient needs.
- Financial Position: Ending 2025 with $140 million in cash, SAB is well-positioned to fund the SAFEGUARD trial through top-line readout and into 2028, ensuring adequate financial resources during critical development phases.
- Technical Advantages: As a fully human anti-thymocyte globulin, SAB-142 avoids the serum sickness and anti-drug antibody issues associated with rabbit ATG, offering better tolerability and redosing capabilities, aimed at inducing T-cell exhaustion to protect pancreatic beta cells and enhance insulin production in patients.
See More
